Dementia with Lewy bodies (DLB) is a type of dementia that shares symptoms with both Alzheimer’s disease and Parkinson’s disease.
If you qualify and agree to be in this study, you will visit the study site for medical tests and assessments approximately 10 times for up to 22 weeks. Most visits will last from one to three hours, and two visits will last longer, potentially four to six hours.
You will be randomly placed into one of two treatment groups. One group will receive the study drug, and the other group will receive a placebo. The placebo looks like the study drug, but contains no active ingredient. The study drug (or the placebo) is a capsule you will take once a day, every morning, with or without food. Neither you nor the study staff will know which group you are in.
Participation is completely free and you are free to stop you participation at any point should you wish.
The study drug is thought to cause an increase in levels of a brain chemical known as cyclic guanosine monophosphate (cGMP). cGMP is a substance involved in how cells communicate with the brain, and increasing cGMP levels in the brain may improve cognitive function.
If you decide to take part, you will sign an informed consent form stating that the study details have been explained to you. However, this is not a contract and you may withdraw from the study for any reason, at any time.
You will be expected to follow the study staff’s instructions, take the study drug as directed, and keep your scheduled appointments.
Patients may qualify for this study if they:
Patients enrolled in this study must have a caregiver, friend, or family member who can provide information about the patient throughout the study. This person will attend all study visits with the subject. We will be happy to give you more information on the study criteria over the phone.
No; however, reasonable travel expenses for attending the study visits may be reimbursed.
The study drug and all study-related care will be provided to you at no cost.